Skip to content
drillr.ai
Sign up

RARE

Ultragenyx Pharmaceutical Inc.

NASDAQ · Healthcare · Biotechnology · US

$15.07
+3.65%
Ask drillr

  • Oct 15, 2026, 15:35 UTC

    Ultragenyx agreed to sell a priority review voucher linked to Fayuvi for $203 million.

    Source:

  • Oct 7, 2026, 16:49 UTC

    Ultragenyx Pharmaceutical Inc. shares rose more than 3.2% on Wednesday morning.

    Source:

  • Oct 7, 2026, 12:30 UTC

    Ultragenyx Pharmaceutical Inc. entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million.

    Source:

  • Oct 2, 2026, 06:00 UTC

    Ultragenyx announced that the European Medicines Agency validated its Marketing Authorisation Application for the investigational gene therapy rebisufligene etisparvovec for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo syndrome Type A).

    Source:

  • Sep 18, 2026, 15:50 UTC

    Ultragenyx Pharmaceutical shares rose 13% following FDA approval of its Sanfilippo syndrome Type A gene therapy Fayuvi.

    Source:

  • Sep 18, 2026, 12:30 UTC

    Ultragenyx (RARE) shares surged 12.6% in the previous trading session on higher-than-average trading volume.

    Source:

  • Sep 18, 2026, 11:51 UTC

    The U.S. FDA approved a drug that Abeona Therapeutics had licensed away, entitling Abeona to collect royalties.

    Source:

  • Sep 17, 2026, 20:01 UTC

    Xenon Pharmaceuticals submitted a New Drug Application to the U.S. Food and Drug Administration for azetukalner for the treatment of focal seizures.

    Source:

  • Sep 17, 2026, 19:48 UTC

    The U.S. FDA approved Ultragenyx's FAYUVI gene therapy, the first-ever approved treatment for Sanfilippo syndrome Type A (MPS IIIA).

    Source:

  • Sep 2, 2026, 20:19 UTC

    Ultragenyx Pharmaceutical announced on Wednesday that its experimental drug for a rare genetic neurodevelopmental disorder failed to meet the primary endpoint in a late-stage trial, causing its shares to plunge 40% in aftermarket trading.

    Source:

  • Aug 19, 2026, 21:21 UTC

    The U.S. FDA approved Ultragenyx's GENGLYCOS gene therapy, the first-ever treatment for the underlying cause of glycogen storage disease type Ia.

    Source:

  • Aug 13, 2026, 07:31 UTC

    Assenagon Asset Management S.A. sold 2,136,807 shares of Ultragenyx Pharmaceutical Inc., reducing its stake by 94.6% during the quarter, as disclosed in a 13F filing.

    Source:

  • Aug 4, 2026, 20:05 UTC

    Ultragenyx Pharmaceutical reported its financial results for the second quarter of 2026, with total revenue of $214 million, including Crysvita revenue of $156 million and Dojolvi revenue of $27 million, and reaffirmed its 2026 financial guidance.

    Source:

  • Jul 27, 2026, 12:00 UTC

    RA Capital and other investors are investing $175 million in Oak Hill Bio to revive an experimental Angelman syndrome drug shelved by Roche.

    Source: